As Peers Fall To Jaw-dropping Valuations And Sell-off, India's Zydus Cadila Bets On JV To Co-exist
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Large companies with well-oiled manufacturing skills and marketing networks in the growing Indian market have demonstrated their attractiveness as buyout targets for multinational companies, but analysts suggest that there could also be a significant interest developing from both sides of the spectrum in signing up proportionately profitable joint ventures for building strong manufacturing assets
You may also be interested in...
Backed By Biosimilars, Vaccines, Transdermals And Respiratory Drugs, India's Cadila Sets Sights On $3 Billion In Sales By 2015
Cadila is said to have allocated $20 million for its Vermont-headquartered unit Zydus Technologies to work on a range of compounds to be delivered via transdermal patches.
Backed By Biosimilars, Vaccines, Transdermals And Respiratory Drugs, India's Cadila Sets Sights On $3 Billion In Sales By 2015
Cadila is said to have allocated $20 million for its Vermont-headquartered unit Zydus Technologies to work on a range of compounds to be delivered via transdermal patches.
Backed By Biosimilars, Vaccines, Transdermals And Respiratory Drugs, India's Cadila Sets Sights On $3 Bil In Sales By 2015
AHMEDABAD, India - In a few months India's Zydus Cadila will join a handful of elite Indian companies like Dr. Reddy's and Cipla that managed to surpass the magic $1 billion mark in annual sales. Cadila says it has a comprehensive blueprint ready to cruise to $3 billion by 2015